Basics Geron Corporation Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat. IPO Date: July 31, 1996 Sector: Healthcare Industry: Biotech Market Cap: $810.28M Activated in VL: True Average Daily Range Avg Daily Range: $0.11 | 2.89% Avg Daily Range (30 D): $0.03 | 2.34% Avg Daily Range (90 D): $0.04 | 2.94% Institutional Daily Volume Avg Daily Volume: 2.81M Avg Daily Volume (30 D): 6.33M Avg Daily Volume (90 D): 7.61M Trade Size Avg Trade Size (Sh.): 346 Avg Trade Size (Sh.) (30 D): 458 Avg Trade Size (Sh.) (90 D): 495 Institutional Trades Total Inst.Trades: 2,731 Avg Inst. Trade: $1.85M Avg Inst. Trade (30 D): $1.43M Avg Inst. Trade (90 D): $1.16M Avg Inst. Trade Volume: .61M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.3M Avg Closing Trade (30 D): $1.32M Avg Closing Trade (90 D): $1.14M Avg Closing Volume: 811.79K     News Oct 23, 2025 @ 10:14 PM GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & S... Source: Bragar Eagel & Squire, P.C. Oct 22, 2025 @ 12:00 PM Cassava Sciences Appoints Dawn C. Bir to the Board... Source: Cassava Sciences, Inc. Oct 13, 2025 @ 8:34 PM Geron Corporation Announces Executive Leadership T... Source: Geron Corporation Aug 19, 2025 @ 12:00 PM SpyGlass Pharma Appoints Elizabeth O’Farrel... Source: Patrick Mooney Aug 13, 2025 @ 11:52 PM GERON (GERN) ALERT: Bragar Eagel & Squire, P.C. is... Source: Bragar Eagel & Squire, P.C. Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.13 $-.02 $-.03 Diluted EPS $-.13 $-.02 $-.03 Revenue $ 164.45M $ 49.04M $ 39.6M Gross Profit $ $ $ Net Income / Loss $ -88.01M $ -16.38M $ -19.84M Operating Income / Loss $ -77.42M $ -12.45M $ -16.7M Cost of Revenue $ $ $ Net Cash Flow $ -38.45M $ -6.01M $ 4.73M PE Ratio